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The purpose of this study is to investigate the bioavailability and glycaemic metabolism of cinnamon oil (CIO) carried by liquid-
loadable tablets (CIO-LLTs), the carrier of a CIO self-emulsifying formulation (CIO-LS). The results of tests performed to evaluate
the physical properties of the CIO-LLT complied with Chinese Pharmacopeia (2010). The release proﬁle suggested that the CIO-
LLT preserved the enhancement of in vitro dissolution of cio. After orally administration, the plasma concentration-time proﬁle
and pharmacokinetic parameters suggested that a signiﬁcant increase (P<0.0001) in the Cmax,A U Ca n dF were observed in
the CIO-LLT. The blood glucose and the HbA1c were signiﬁcantly decreased in alloxan-induced hyperglycemic rats (P<0.05,
P<0.01, resp.), while the level of insulin secretion was markedly elevated in alloxan-induced hyperglycemic rats (P<0.05). The
alloxan-damaged pancreatic β-cells of the rats were partly recovered gradually after the rats were administered with CIO-LLT 45
days later. CIO-LLT could improve the bioavailability and glycaemic metabolism of CIO.
1.Introduction
According to the World Health Organization, it is estimated
that approximately 150 million people worldwide have di-
abetes mellitus at present [1]. Therefore, new therapeutic
approaches are needed to treat diabetes more eﬃciently.
Presently, there is growing interest in herbal remedies due to
the side eﬀects associated with the oral hypoglycemic agents
forthetreatmentofdiabetesmellitus[2].Theplantkingdom
is a wide ﬁeld to search for natural eﬀective oral hypo-
glycemic or hypolipidemic agent that has slight or no side
eﬀects. More than 400 plants with glucose lowering eﬀect are
known [3]. They might be used in various forms like food
and medicines, which contain both organic and inorganic
constituents.
Cinnamon is one of the well-known and oldest spices,
which has been used for centuries in several cultures [4]. It
has been traditionally used in Ayurvedic and Chinese medi-
cine as a treatment for diabetes [5]. Research has shown that
cinnamon oil (CIO) is particularly very helpful for patients
suﬀering from type 2 diabetes. However, the poor water-
soluble drug, cinnamon oil, leads to poor dissolution and
bioavailability. To overcome these problems, various formu-
lation strategies such as cyclodextrin, surfactants, nanoparti-
cles, lipids carriers, and solid dispersions are reported [6].
In recent years, much attention has been focused on self-
emulsifying drug delivery systems (SEDDSs), which are iso-
tropic mixtures of oil, surfactant, cosurfactant, and drug that
form ﬁne oil-in-water emulsion when introduced into aque-
ous medium under gentle agitation [7–9]. SEDDSs have
shown a reasonable success in improving oral bioavailability
of poorly water soluble drugs [10, 11].
However,SEDDSsareusuallyformulatedinaliquidform
whichhas some disadvantages suchas high productioncosts,
low drug incompatibility, and poor physical and chemical
stability. The incorporation of the self-emulsifying mixture
into a solid dosage form is desirable as it combines the ad-
vantages of SEDDS (high solubility and bioavailability) with
those of solid dosage forms (high stability). The transforma-
tion of liquid lipid systems into a solid oral dosage form has
been attempted by several methods such as capsule ﬁlling,
spray drying, adsorption onto solid carriers, and melt
granulation as well as other techniques [12–15]. The tablet is
the most popular dosage form in use today. It is simple and2 The Scientiﬁc World Journal
convenient to use. Liquid-loadable tablets (LLTs), prepared
by direct compression of solid carrier particles and subse-
quentlyloadingtheliquidintothetablet,haveahigherliquid
loading [16]. The work presented in this paper focuses on
the pharmacokinetic (PK) performance of CIO from loaded
LLT and the eﬀects of CIO-loadable tablets (CIO-LLT) on
glycaemic metabolism.
2.MaterialsandMethods
2.1. Animals. Healthy male adult Wistar rats (2 months old
and weighing 225 ± 25g) were used in the study. The study
was approved by Shandong University’s ethics committee,
and all procedures complied with the guidance set out in the
Guidelines for Caring for Experimental Animals published
by the Ministry of Science and Technology of China. Every
care was taken to minimize discomfort, distress, and pain.
2.2. Materials. Cinnamon oil was obtained from Shanghai
Yansheng biotechnology Co., Ltd. China. Magnesium alu-
minometasilicate (MAS) was obtained from Jinan Kailida
Chemical Technology Co., Ltd China.
2.3. Preparation of CIO-Loaded SEDDS (CIO-LS). Based on
the pilot studies, the blank SEDDSs were prepared by mixing
of 30% Miglyol 812 (oil), 60% Cremophor RH40 and Tween
80 (surfactant, 2:1), and 10% Transcutol P (cosurfactant)
at 50◦C with a magnetic stirrer. Then CIO and Aerosil 200
(1000mg) suspended in 150mL ethanol were dissolved in
the blank SEDDS with stirring until forming an isotropic
mixture. The mixture was then kept at room temperature
and equilibrating for 24h.
2.4. Reconstitution Properties of the SEDDS. The emulsiﬁ-
cation time of the SEDDS formulations was evaluated ac-
cording to the way described in detail by Xi et al. [17]. In
brief, SEDDS (250μL) was introduced into 500mL of dis-
tilled water at 37◦C under gentle agitation by a standard
stainless steel dissolution paddle rotating at 50rpm. The
emulsiﬁcation time was assessed visually. All experiments
were carried out in triplicates.
Droplet size was determined by Zetasizer Nano ZS (Jinan
Runzhi Instruments, China) with dynamic light scattering
particle size analyzer at a wavelength of 635nm and at a
scattering angle of 90◦ at 25◦C. All studies were repeated
three times, and the values of z-average diameters were used.
The z-average diameter, also referred to as the harmonic
intensity-weighted average hydrodynamic diameter, of the
emulsions was derived from cumulated analysis by the Au-
tomeasure software. Zeta potential of the emulsion formed
after addition of SEDDS into 0.1N HCl solution was meas-
ured using Zetasizer Nano ZS.
2.5. Preparation of LLT. The composition of LLT was MAS/
magnesium stearate (99.5:0.5 w/w%)[16]. The additive was
required during the tabletting process to avoid undesired
adhesion of MAS powder to the tablet punches when
under compression. Tablets of approximately 250mg were
compressed using a round 12mm ﬂat-faced punch. Tablet
hardness was determined using a hardness tester. Tablet dis-
integration was performed in 0.1N HCl using an automatic
disintegrationtester(JB-1,TianjianXinzhou,China)accord-
ing to the conditions of the Chinese Pharmacopoeia (2010)
for uncoated tablets.
2.6. Loading of CIO in to Tablet. Tablets were placed in excess
of CIO-SEDDS and allowed to absorb the liquid until a con-
stant tablet weight was reached. Before weighing, excess of
liquid on the surface of the tablets was removed by tissue
paper. After few hours of storage, the tablet surface is dry,
comparable to the nonloaded tablet [18].
2.7. Characterization of CIO-Loaded Tablet (CIO-LLT). Tab-
lets were evaluated by performing quality control tests for
uniformity of drug content, friability, disintegration, hard-
ness, and weight variation. All tests were carried out in trip-
licates and according to Chinese Pharmacopoeia (2010).
2.8. In Vitro Drug Release Study. CIO-LS and CIO-LLT were
tested in vitro in 950mL puriﬁed water at 37◦C using rotat-
ing basket apparatus (Chinese Pharmacopoeia) at a rotation
speedof100rpm.Sampleswerewithdrawnatpredetermined
time intervals and then mixed with 150μL of methanol
containing 1.75μgo fα-naphthoﬂavone. The resultant solu-
tion was ﬁltered, and an aliquot (100μL) of the ﬁltrate was
s u b j e c t e dt oH P L Ca n a l y s i s .
2.9. In Vivo Protocols. Wistar rats were divided randomly
into four groups (six animals in each group). The ﬁrst group
(CIO) was treated orally (100mg/kg) CIO formulated in
normal saline containing 3% Tween 80. Group II (CIO-LS)
and group III (CIO-LLT) were treated orally CIO-SEDDS
(100mg CIO/kg) and CIO-LLT (100mg CIO/kg), respec-
tively. Group IV was treated (i.v.) CIO sample (100mg/kg)
used as control group. Before dosing, the rats were fasted
overnight. Food was given minimum 2h after dosing. A
3mL blood samples were drawn from the tail vein before
dosing and at the following times: 15min, 30min, 45min,
1h, 1.5h, 3h, 4h, 6h, and 24h after dosing. Blood samples
were centrifuged at 3000g for 10min, and plasma samples
wereharvested.Eachplasmasample(100μL)wasmixedwith
200μLofMethanol,vortexed, andcentrifugedat16,000gfor
5min. The supernatant was ﬁltered with a 0.45-μm syringe
ﬁlter, and 100μL of the ﬁltrate was subjected to HPLC
analysis.
2.10. Pharmacokinetic Parameter Analyses. Pharmacokinetic
parameters were calculated from the corresponding plasma
concentration-timecurvesusingnoncompartmentalanalysis
(WinNonlin 4.0, Pharsight, Mountain View, CA, USA). The
area under the plasma concentration-time curve from time 0
to time inﬁnity (AUC0–∞), Cmax,Tmax were determined from
the concentration-time proﬁle. The absolute bioavailability
(F) was calculated using the following equations:
F =

AUCoral/i.p. ∗Dosei.v.


AUCi.v. ∗ Doseoral/i.p.
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2.11. Estimation of CIO-LLT on Glycaemic Metabolism. Ani-
mals were fasted for 12h and were then injected (i.v.) with
alloxan(75mg/kg)solutionthatwasmadewithsaline.Forty-
eight hours later, blood samples were collected from the tail
veins of the rats. The blood glucose was analyzed with a
Glucometer-4 (Bayer). The blood glucose level of rats greater
than 11.1mmol/L was selected as hyperglycemic rats.
Forty hyperglycemic rats were selected and randomly
divided into 4 groups. The ﬁrst group (CIO) was treated
orally (100mg/kg) CIO formulated in normal saline con-
taining 3% Tween 80. Group II (CIO-LS) and group III
(CIO-LLT)weretreatedorallyCIO-SEDDS(100mgCIO/kg)
and CIO-LLT (100mg CIO/kg), respectively. Group IV was
treated orally saline used as control group. On the 45th day,
blood samples were collected from the orbital veins to mea-
sure the to determine the blood glucose levels and HbA1c
with the HbA1c Apparatus (Variant II, Bio-Rad Laborato-
ries) and insulin with an enzyme-linked immunosorbant
assay (ELISA) kit (Shanghai Jinma Biological Technology,
Inc., China), respectively. Then, the rats were sacriﬁced.
The pancreas was dissected out and placed in 10% buﬀered
formalinand the liverwasdissected outforthe measurement
of hepatic glycogen.
2.12. Data Analysis. The data are expressed as mean ± SEM.
Statistical signiﬁcance was tested by two-tailed Student’s t-
test for diﬀerences between two groups and by one-way
ANOVAcarriedoutusingtheSASstatisticalpackage(version
8.1, SAS Institute, Cary, NC, USA) for testing diﬀerences
between means for more than two groups. Statistical signiﬁ-
cance level was set at P<0.05.
3. Results andDiscussion
The work presented in this paper focuses on the ability of
LLT prepared from MAS to be loaded with a SEDDS system
containing CIO, the pharmacokinetic (PK) performance of
CIO from loaded LLT and the eﬀects of CIO-loadable tablets
(CIO-LLT) on glycaemic metabolism. MAS is nontoxic and
consists of highly porous spherical particles with a median
size of 110μma n das p e c i ﬁ cs u r f a c ea r e ao fa p p r o x i m a t e l y
370–420m2/g [16]. Due to its excellent ﬂuidity and com-
pressibility, MAS can be mechanically compacted into stable
tablets. The mechanical stability of the unloaded LLT was
29N ± 8% (n = 10). Disintegration time of the unloaded
LLT was 0.27±0.11min. It was the time taken by each of the
6 tablets to pass completely through the 10 mesh screen.
3.1. Reconstitution Properties of the SEDDS. SEDDS formu-
lation disperse quickly and completely when subjected to
aqueous environment under mild agitation. The eﬃciency of
self-emulsiﬁcation can be estimated by measuring the rate
of emulsiﬁcation and the droplet size distribution [19]. As
shown in Table 1, emulsiﬁcation time was 23s for SEDDS. It
ismuchrelatedtotheirhydrophilic-lipophilicbalance(HLB)
value of surfactant and cosurfactant.
It has been reported that any change in interfacial ﬁlm
inﬂuences the surface curvature of the droplet leading to
diﬀerences in the droplet size [20–22]. As shown in Table 1,
Table 1: Reconstitution properties of the SEDDS.
SEDDS
Emulsiﬁcation time (seconds) 23 ±3
Zeta potential +2.00 ±0.30
Droplet size (nm) 132.5
Polydispersity index (PDI) 0.160 ±0.020
Values are shown as means ± SD.
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Figure 1: Correlation between SEDDS loading and loading time.
the z-average droplet sizes for SEDDS system was 132.5nm.
The mean droplet size and size distribution (polydispersity
index) was 0.160. SEDDS showed a zeta potential of
+2.00mV, therefore providing prolonged stabilization.
3.2. Loading of LLT. A series of absorption experiments
was conducted to explore the loading capacity of the LLT.
Figure 2 illustrates the absorption proﬁles of SEDDS into
the LLT as a function of exposure time and the compression
force. As shown in Figure 1, application of higher compres-
sion force during tablet compression increased the loading
time and reduced the maximum theoretical loading amount.
The loading process can be seen as the replacement of air in
the tablet pores by liquid. It is consistent with the Washburn
equation [23]: v = r2/8μeﬀ ∗ pc/d where v is the velocity
of the interface between air and liquid, r is the radius and d
the length of a pore, pc the capillary pressure and μeﬀ is the
eﬀective viscosity. According to the equation, the capillary
ﬂow in the loading process is controlled mainly by capillary
action. The fast absorption is caused by capillary suction and
is determined by both the pore size distribution of LLT, the
nature of the liquid viscosity and liquid-solid contact angle
[16]. The higher compression pressure applied would cause
the formation of smaller pore size distribution [18]. It may
explainwhytheloadingtimeincreasesathighercompression
pressures and why the LLT subjected to higher compression
pressure absorbed lower theoretical amount of SEDDS.
3.3. Characterization of CIO-Loaded Tablet. Table 2 shows
the results of tests performed to evaluate the physical proper-
ties of the CIO-loaded tablet according to Chinese Pharma-
copoeia (2010). It is clear that CIO-loaded tablet complied4 The Scientiﬁc World Journal
Table 2: Characteristics of the CIO-loaded tablet.
CIO-loaded tablet
Average CIO contents (% ± SD) 96.11 ± 1.5
Friability (% ± SD) 0.60 ±0.18
Hardness (N ± SD) 30.1 ± 7.00
Disintegration time (min ± SD) 0.31 ±0.20
Weight variation (mg) 1.55 ±0.022
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Figure 2: Drug release proﬁles of the SEDDS and LLT.
with the required speciﬁcations and standard regarding drug
content uniformity. CIO-loaded tablet complied with Chi-
nesePharmacopeiafriabilitytestasthefriabilitywaslessthan
1% and there were no broken tablets. For the disintegration
timeresults,CIO-loadedtabletshowedveryshortdisintegra-
tion time (0.31 ± 0.20 seconds). Also, the CIO-loaded tablet
passed the Chinese Pharmacopeia weight variation test.
3.4. In Vitro Drug Release Study. Drug release rate and the
cumulative percent of CIO dissolved into the aqueous medi-
um are important criteria that govern the quality of the LLT.
Thephysicalpropertiesoftheingredientsusedtopreparethe
LLT have a profound eﬀect on the CIO release rate. Drug
release proﬁles of the CIO-tablet and CIO-SEDDS are shown
in Figure 2. The CIO dissolution from both SEDDS and LLT
formulationstookplaceimmediately.Thefastdrugreleaseof
the LLT may be explained by both an increase in the speciﬁc
surface area of the drug resulting from the adsorption to
the highly MAS porous spherical particles and possibly an
amorphous state of the drug. The solid carrier, MAS, used
in the LLT did not interfere the dissolution of CIO from the
SEDDS. The results of the release proﬁle suggested that the
LLT preserved the enhancement of in vitro dissolution of
CIO and would eventually enhance the dissolution of drug
in vivo.
3.5. Pharmacokinetics of CIO-Loaded Tablet. Figure 3 shows
plasma concentration-time curves of CIO after adminis-
tration of three diﬀerent formulations. The calculated phar-
macokinetic parameters are summarized in Table 3.A f t e r
Table 3: Pharmacokinetic parameters after oral administration of
CIO, CIO-LS, and CIO-LLT to rats.
Groups AUC0→24h
(μgh / m L )
Cmax
(μg/mL) Tmax (h) F (%)
CIO-LS 1.96 0.51 ±0.30 0.15 ±0.09 2.5
CIO-LLT 1.68 0.43 ±0.21 0.18 ±0.12 2.2
C I ON AN AN A 0
Values are shown as means ± SD. ∗P<0.0001, NA: Not applicable. (n = 6).
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Figure 3: Mean whole blood concentrations of CIO in rats
following oral doses of 100mg in the form of CIO-SEDDS and
CIO- LLT. The total plasma concentrations of drug after oral
administration of CIO could not be detected.
orally administration, only the plasma concentration-time
proﬁle and pharmacokinetic parameters of SEDDS and LLT
could be obtained at the dose of 100mg/kg. The data of
CIO were not meaningful because plasma levels of CIO were
either below detectable limit and they were not high enough
for accurate pharmacokinetic analysis. In the case of SEDDS
(CI-LS), CIO was rapidly absorbed (Tmax,0 .15 ± 0.09h)
reaching a Cmax of 0.51 ± 0.30μg/mL. In the case of LLT
(CIO-LLT), CIO was absorbed (Tmax,0 .18±0.12h) reaching
a Cmax of 0.43±0.21μg/mL. The bioavailability of CIO from
each of the 3 formulations, estimated as the area under the
whole blood curve was 0, 2.5% and 2.2%, respectively. It was
compared using two-tailed Student’s t-test. It did not show
any statistically signiﬁcant diﬀerences between the CIO-LS
and CIO-LLT.
A signiﬁcant increase (P<0.0001) in the Cmax, AUC and
F were observed in the CIO-LLT group when compared with
the CIO group. Thus, the higher plasma concentrations of
CIO in LLT were contributed by improving the solubility of
drug by SEDDS.
3.6. Eﬀects of CIO-LLT on Glycaemic Metabolism. Alloxan
is the most prominent diabetogenic chemicals in diabetes
research. It is toxic glucose analogues that preferentially ac-
cumulate in pancreatic beta cells via the GLUT2 glucose
transporter [24, 25]. Alloxan has two distinct pathological
eﬀects: it selectively inhibits glucose-induced insulin secre-
tion through speciﬁc inhibition of glucokinase, the glucose
sensor of the beta cell, and it causes a state of insulin-
dependentdiabetesbyselectivenecrosisofbetacellsintype1The Scientiﬁc World Journal 5
(a) (b) (c) (d)
Figure 4: Islet cell death and replication represented by hematoxylin-eosin.
Table 4: Eﬀect of CIO, CIO-LS and CIO-LLT on blood glucose and
HbA1c levels in alloxan-hyperglycemic rats.
Diﬀerent groups Blood glucose (mmol/L) HbA1c
Control group 21.2 ±2.11 1 .8 ±0.23
CIO-LS-treated 10.4 ±3.0∗ 7.0 ±0.31∗∗
CIO-LLT-treated 12.5 ±2.1∗ 7.9 ±0.20∗∗
CIO-treated 19.9 ±2.71 1 .0 ±0.20
Values are means ± SEM, n = 10. ∗P<0.05, ∗∗P<0.01 versus Control
group.
Table 5: Eﬀect of CIO, CIO-LS and CIO-LLT on serum insulin and
hepatic glycogen level in alloxan-induced diabetic rats.
Diﬀerent groups Serum insulin (μU/mL) Hepatic glycogen
(mg/g tissue)
Control group 3.9 ±1.41 3 .3 ±3.6
CIO-LS-treated 8.9 ±0.7∗∗ 17.6 ±0.5∗
CIO-LLT-treated 6.8 ±0.5∗∗ 16.8 ±0.6∗
CIO-treated 4.3 ±0.41 3 .8 ±0.5
Values are means ± SEM, n = 10. ∗P<0.05, ∗∗P<0.01 versus Control
group.
and type 2 diabetes mellitus [24, 25]. So alloxan is the agent
of choice for induction of diabetic experimental animals in
this study.
The results of blood glucose from hyperglycemic rats
induced by alloxan are presented in Table 4. The levels of
blood glucose decreased after administration of CIO-LS and
CIO-LLT (P<0.05). CIO-LS and CIO-LLT could decrease
the concentration of HbA1c in plasma of alloxan-induced
hyperglycemic group 45 days later (P<0.01), as shown in
Table 4. However the same result did not occur in the CIO
group.
The mechanisms of the hypoglycaemic eﬀect of CIO-
LS and CIO-LLT have been also studied in this paper. As
shown in Table 5, the levels of serum insulin elevated after
administration of CIO-LS and CIO-LLT. However, the same
results did not occur in the saline treated group (3.8 ±
0.4μU/mL) throughout the total duration of the study. It
is possible that CIO bring about release of insulin from
the surviving β-cells, as well from the recovered β-cells by
CIO. The β-cells of the rats fed with CIO-LS and CIO-LLT
were partly recovered (Figures 4(a) and 4(b)). β-Cells death
and alteration of islet cell population were prominent in
the diabetic rats that fed with CIO (Figure 4(c)) and saline
(Figure 4(d)).
Glycogen storage in the liver is another way to maintain
blood glucose concentration in mammals. Decreased hepatic
glucose production is induced by glycogen synthesis. CIO-
LS and CIO-LLT produced the increase in the level of hepatic
glycogen. Concentrations of hepatic glycogen were lower in
saline-treated rats than CIO-treated rats (Table 5). However,
there is no signiﬁcant diﬀerence between them (P>0.05).
4. Conclusion
The work presented in this paper focuses on the ability of
LLT prepared from MAS to be loaded with a SEDDS system
containing CIO. It combines the advantages of SEDDS (high
solubility and bioavailability) with those of solid dosage
forms (high stability). CIO-loaded tablet could improve the
glycaemic metabolism of CIO. It was contributed by improv-
ing the bioavailability drug by SEDDS.
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